Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 8 articles:
HTML format
Text format

Single Articles

    January 2019
  1. COMPSTON JE, McClung MR, Leslie WD
    Lancet. 2019;393:364-376.
    PubMed     Text format     Abstract available

    May 2018
  2. KENDLER DL, Geusens P, Zerbini CAF, Minisola S, et al
    Teriparatide vs risedronate for osteoporosis - Authors' reply.
    Lancet. 2018;391:1896.
    PubMed     Text format    

  3. LIEL Y
    Teriparatide vs risedronate for osteoporosis.
    Lancet. 2018;391:1895.
    PubMed     Text format    

    November 2017
  4. HARVEY NC, McCloskey E, Kanis JA, Compston J, et al
    Bisphosphonates in osteoporosis: NICE and easy?
    Lancet. 2017;390:2243-2244.
    PubMed     Text format    

    Prevention of fractures in patients with osteoporosis.
    Lancet. 2017 Nov 9. pii: S0140-6736(17)32167.
    PubMed     Text format    

  6. KENDLER DL, Marin F, Zerbini CAF, Russo LA, et al
    Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Lancet. 2017 Nov 9. pii: S0140-6736(17)32137.
    PubMed     Text format     Abstract available

    July 2017
  7. LANGDAHL BL, Libanati C, Crittenden DB, Bolognese MA, et al
    Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
    Lancet. 2017 Jul 26. pii: S0140-6736(17)31613.
    PubMed     Text format     Abstract available

    Bone-forming agents in non-responders to bisphosphonates.
    Lancet. 2017 Jul 26. pii: S0140-6736(17)31824.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Osteoporosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.